Know Cancer

forgot password

Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype

Phase 1
18 Years
Not Enrolling
B Cell Lymphoma, Follicular Lymphoma, Neoplasm

Thank you

Trial Information

Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype

The idiotype of the immunoglobulin on a given B cell malignancy (Id) can serve as a clonal
marker, and a previous pilot study in lymphoma patients has demonstrated that autologous Id
protein can be formulated into an immunogenic, tumor specific antigen by conjugation to a
carrier protein (KLH) and administration with an emulsion-based adjuvant.

The objectives of this study are: 1) to evaluate feasibility and toxicity of new vaccine
formulations, and 2) to evaluate cellular and humoral immune responses against the unique
idiotype of the patient's lymphoma.

The goal of this study is to treat patients with follicular lymphomas to complete remission
or minimal residual disease with chemotherapy. Six to twelve months after completion of
chemotherapy, in an effort to reduce the relapse rate (by eradicating microscopic disease
resistant to chemotherapy), patients will receive one of two new formulations of an
autologous Id vaccine.

Inclusion Criteria


Sample size: up to 30 patients.

Sex distribution: Male and female.

Age: Patients must be greater than or equal to 18 years old.

Patients must meet all of the following eligibility criteria:

Tissue diagnosis of: follicular small cleaved cell or follicular mixed lymphoma with
surface IgM, IgA, or IgG phenotype with a monoclonal heavy and light chain. Pathology
slides must be submitted to the NIH Pathology Department for review.

Stage III or IV lymphoma.

A single peripheral lymph node of at least 2x2 to 3x3 cm size and accessible for

Karnofsky status greater than or equal to 70%.

Life expectancy of greater than 1 year.

Serum creatinine less than or equal to 1.5 mg/dl unless felt to be secondary to lymphoma.

Bilirubin less than or equal to 1.5 mg/dl unless felt to be secondary to lymphoma or
Gilbert's disease. SGOT/SGPT less than or equal to 3.5 x upper limit of normal.

Ability to give informed consent. Ability to return to clinic for adequate follow-up for
the period that the protocol requires.

There are no gender or racial / ethnic restrictions on patient selection. This protocol is
open to all genders and racial / ethnic groups.


The presence of any exclusion criteria (listed below) will prohibit entry onto study:

Prior total body irradiation.

Presence of antibodies to HIV or hepatitis B surface antigen or other active infectious

Pregnant or lactation. Fertile men and women must plan to use an effective contraception.
A beta-HCG level will be obtained in women of child-bearing potential.

Patients with previous or concomitant malignancy, regardless of site, except curatively
treated squamous or basal cell carcinoma of the skin, or effectively treated carcinoma in
situ of the cervix.

Patient unwilling to give informed consent.

Failure to meet any of the eligibility criteria in Section 3.2.

Any medical or psychiatric condition that in the opinion of the protocol chairman would
compromise the patient's ability to tolerate this treatment.

Patients with CNS lymphoma (current or previously treated) will not be eligible.

Type of Study:


Study Design:

Primary Purpose: Treatment


United States: Federal Government

Study ID:




Start Date:

January 1997

Completion Date:

November 2010

Related Keywords:

  • B Cell Lymphoma
  • Follicular Lymphoma
  • Neoplasm
  • B-Cell Lymphoma
  • BCL- 2 Positive Tumor
  • Immunization
  • Induction Chemotherapy
  • Lymphoma Vaccine
  • Follicular Lymphoma
  • Tumor-Derived Immunoglobulin Idiotype
  • Neoplasms
  • Lymphoma
  • Lymphoma, Follicular
  • Lymphoma, B-Cell



National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland  20892